Providing a VOICE for Texas' MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1988
Community (Members Only)
Meetings & Education
Articles and Blogs
Fellows Abstract Competition
Patient Advocacy Organizations
Advocacy Engagement Pilot
State & Federal Resources
FDA Oncology Drug Approvals
Find A Clinical Trial
Off-Label Use Literature
Financial Advocacy & Patient Assistance
Become a Corporate Member
NEW FDA APPROVALS IN ONCOLOGY: 2020 HIGHLIGHTS
20 novel drugs from 19 different companies were approved for 15 different conditions.
In addition, 2 approvals were for new formulations of already marketed drugs—Onureg
) and Darzalex Faspro
daratumumab and hyaluronidase-fihj
For the first time ever, more than half of the approvals (11) were “accelerated” (i.e., based on intermediate endpoints). Continued approval for these drugs may depend on verification of clinical benefit.
Tyrosine kinase inhibitors constituted the largest single drug “type” (there were 7), while drug conjugates were the 2nd largest modality (4).
Approvals were about evenly divided between oral and infused/injected agents (9 and 11, respectively).
Seven of the approvals specify genetic alterations that should be incorporated into patient selection.